Tag: neurogenetic testing market forecast

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Neurogenetic Testing Market In 2029?

The neurogenetic testing market has experienced a swift surge in recent years. The market size will expand from a size of $0.61 billion in 2024 to $0.7 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.9%. This significant growth during the historic period can be accredited to factors such as a heightened incidence of neurological diseases, increased life science research, a rising prevalence of Parkinson’s disease, a growth in cancer cases and an increase in consciousness among healthcare professionals.

What Growth Rate Is Forecasted for the Neurogenetic Testing Market by 2029?

The market size for neurogenetic testing is predicted to considerably expand in the coming years, with anticipated growth to a value of $1.16 billion by 2029, and a compound annual growth rate (CAGR) of 13.5%. The forecasted growth can be linked to the proliferation of personalized medicine applications, the prevalence of chronic diseases, an uptick in hospitals and diagnostic laboratories, and an intensified focus on early disease detection. Key trends for this forecast period involve technological advancements, increased uptake of non-invasive testing procedures, the development of new products, strategic partnerships, and the rise of innovative biomarkers related to neurological disorders.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Which Key Companies Are Shaping the Future of the Neurogenetic Testing Market?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Which Factors Are Driving Demand in the Neurogenetic Testing Industry?

The neurogenetic testing market is poised for growth, spurred on by the increasing incidence of neurological disorders. These disorders, affecting the brain, spinal cord, and nerves, can be attributed to genetic predisposition, trauma, toxins, infections, autoimmune reactions, and degeneration. Neurogenetic testing is a powerful tool in diagnosing, managing, and treating these disorders as it offers personalized genetic risk assessments, informing treatment plans and enabling patients and families to make knowledgeable health decisions, which enhances patient care and outcomes. For instance, the Belgium-based non-profit organization, the European Brain Council, reported in April 2022, that there are currently over 600 neurological diseases and close to 300 psychiatric conditions affecting millions worldwide, including 65 million with epilepsy. Additionally, in Europe, there are currently 10.5 million people suffering from dementia, a number predicted to increase to 18.7 million by 2050. Hence, this increase in neurological disorders is anticipated to fuel the growth of the neurogenetic testing market.

Neurogenetic Testing Market Driver: Surging Cancer Cases Fosters Expansion of Neurogenetic Testing Market

 

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

How Is the Neurogenetic Testing Market Segmented by Several Divisions?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

What are the Emerging Market Trends Driving the Growth of the Neurogenetic Testing Industry?

Prominent businesses in the neurogenetic testing market are focusing on the advancement of novel products, such as whole-genome sequencing, to boost the precision and extent of genetic examination, thereby promoting exhaustive and customized testing for neurological diseases. Whole-genome sequencing (WGS) is an all-encompassing genetic examination method, which involves the assessment of the complete DNA sequence of a person’s entire genome. For instance, Nucleus Genomics, an American genetic analysis provider, unveiled a DNA analysis offering in March 2024. This platform provides individuals with a more profound comprehension of their genetic predispositions, enabling them to make knowledgeable decisions regarding their health and wellness. Leveraging advanced technology and exceptional genetic counseling services, Nucleus Genomics is poised to transform the genetic testing field, bringing whole-genome sequencing directly to individuals and revolutionizing genomic medicine.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Which Regions Are Driving Growth in the Neurogenetic Testing Market?

North America was the largest region in the neurogenetic testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16131

This Report Delivers Insight On:

1. How big is the neurogenetic testing market, and how is it changing globally?

2. Who are the major companies in the neurogenetic testing market, and how are they performing?

3. What are the key opportunities and risks in the neurogenetic testing market right now?

4. Which products or customer segments are growing the most in the neurogenetic testing market?

5. What factors are helping or slowing down the growth of the neurogenetic testing market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Factors Are Propelling the Market Growth of theNeurogenetic Testing Market from 2025 to 2034?

Growing cases of neurological disorders are boosting the neurogenetic testing market. These disorders stem from genetics, trauma, and degeneration. Neurogenetic testing personalizes care and guides treatment. In April 2022, the European Brain Council reported over 600 neurological and 300 psychiatric conditions affect millions globally. Europe alone has 10.5 million dementia cases, expected to reach 18.7 million by 2050. This demand supports the market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

#What is the Projected CAGR for the Neurogenetic Testing Market Size from 2025 to 2034?

The neurogenetic testing market size has expanded rapidly in recent years. It is projected to increase from $0.61 billion in 2024 to $0.7 billion in 2025 at a CAGR of 13.9%. Growth is driven by rising neurological disease prevalence, increased life sciences research, growing Parkinson’s disease cases, cancer cases, and awareness among healthcare providers.

The neurogenetic testing market is projected to grow to $1.16 billion in 2029, at a CAGR of 13.5%. Growth is driven by the expansion of personalized medicine applications, rising chronic diseases, more hospitals and diagnostic labs, and demand for early disease detection. Key trends include technological advancements, non-invasive testing, new product development, strategic collaborations, and novel biomarkers.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16131

How Are Market Trends and Innovations Revolutionizing theNeurogenetic Testing Industry in Recent Times?

Major companies in the neurogenetic testing market are implementing comprehensive techniques like whole-genome sequencing to broaden genetic analysis capabilities. In March 2024, Nucleus Genomics, a US-based company, released a DNA analysis product offering insights into genetic predispositions, supported by advanced technology and genetic counseling to empower personalized health decisions.

Which Key Market Players Are Shaping the Future and Growth of theNeurogenetic Testing Market?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

What Are the Core Segments of the Neurogenetic Testing Market, and How Do They Contribute to Growth?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

What Regions Are Dominating the Neurogenetic Testing Market Growth?

North America was the largest region in the neurogenetic testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Neurogenetic Testing Market 2025, By The Business Research Company:

Prenatal And Newborn Genetic Testing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/prenatal-and-newborn-genetic-testing-global-market-report

Molecular Cytogenetics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/molecular-cytogenetics-global-market-report

Genetically Modified Animal Products Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/genetically-modified-animal-products-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Discover trends, market shifts, and competitive outlooks for the neurogenetic testing industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Projected CAGR for the Neurogenetic Testing Market Size from 2025 to 2034?

The market size of neurogenetic testing has experienced a significant upturn in recent times. The forecast sees a surge from $0.61 billion in 2024 to $0.7 billion in 2025, with a compound annual growth rate (CAGR) of 13.9%. Factors that contributed to this historical growth include the higher incidence rates of neurological diseases, heightened research activity in the life sciences sector, an increased prevalence of Parkinson’s disease, a rising number of cancer cases, and growing consciousness amongst medical professionals.

The market size for neurogenetic testing is anticipated to experience swift expansion over the next few years. The market is projected to reach $1.16 billion in 2029, boasting a compound annual growth rate (CAGR) of 13.5%. This growth during the forecast period can be credited to the surge in personalized medicine applications, the rise in chronic illnesses, a growing count of hospitals, an upswing in diagnostic labs, and an increasing demand for early disease diagnosis. Key trends forecast for this period include the advancements in technology, a higher frequency of non-invasive testing methods, the development of new products, strategic partnerships, and the emergence of new biomarkers pertinent to neurological disorders.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

What Are the Core Growth Drivers Propelling the Neurogenetic Testing Market Forward?

The escalating numbers of neurological conditions are anticipated to stimulate the development of the neurogenetic testing sector. Neurological conditions pertain to any disease impacting the nervous system, including the brain, spinal cord, and nerves. The emergence of these conditions can be attributed to genetic vulnerability, infections, trauma, toxins, autoimmune reactions, and degeneration. Neurogenetic assessments significantly boost the diagnosis, treatment, and management of these disorders by providing personalized insights on genetic risk elements, informing treatment options, and enabling individuals and families to make knowledgeable healthcare decisions, consequently enhancing patient care and outcomes. For example, in April 2022, based on data from the European Brain Council, a non-profit organization from Belgium, over 600 neurological and nearly 300 psychiatric conditions afflict millions worldwide, including 65 million who suffer from epilepsy. In Europe, dementia affects 10.5 million people, with forecasts predicting a surge to 18.7 million by 2050. As a result, the escalating numbers of neurological conditions are predicted to impel the development of the neurogenetic testing sector.

Neurogenetic Testing Market Driver: A Surge in Cancer Cases Promotes Growth in Neurogenetic Testing Market

 

Which Key Market Segments Comprise the Neurogenetic Testing Market and Drive Its Revenue Growth?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Neurogenetic Testing Market?

North America was the largest region in the neurogenetic testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing the Neurogenetic Testing Industry Evolution?

Big players in the neurogenetic testing market are focused on delivering innovative products, such as whole-genome sequencing in an attempt to improve the precision and range of genetic analysis, thereby providing more thorough and personalized tests for neurological conditions. Whole-genome sequencing (WGS) constitutes a detailed method of genetic testing that discerns the full DNA sequence of a person’s entire genome. For instance, in March 2024, Nucleus Genomics, a company based in the USA that specializes in genetic analysis, unveiled a novel product for DNA analysis. This platform equips people with a comprehensive understanding of their genetic predispositions which in turn aids them in forming knowledgeable decisions regarding their health and overall well-being. Armed with advanced technology and proficient genetic counseling services, Nucleus Genomics is poised to redefine the genetic testing landscape, making whole-genome sequencing directly accessible to individuals and bringing about a revolution in genomic medicine.

View the full report here:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

How Is the Neurogenetic Testing Market Conceptually Defined?

Neurogenetic testing is a type of genetic testing that focuses on identifying genetic variations associated with neurological disorders or conditions affecting the nervous system. It is used for diagnosing, predicting, and managing neurological disorders, as well as facilitating research and the development of personalized treatment approaches in the field of neurology and genetics.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16131

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the neurogenetic testing market size evolved in recent years?

The scale of the neurogenetic testing market has experienced rapid expansion lately. Its growth is anticipated to increase from $0.61 billion in 2024 to $0.7 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 13.9%. The significant development during the historic period is a result of the rise in the occurrence of neurological ailments, expanded research in the life science sector, a growing number of Parkinson’s disease patients, elevated cancer cases, and heightened awareness among healthcare experts.

What are the predictions for the neurogenetic testing market size in the coming years?

The market size for neurogenetic testing is projected to experience a swift expansion in the coming years, reaching $1.16 billion in 2029 with a 13.5% compound annual growth rate (CAGR). This growth during the forecast period is likely due to a variety of factors including an increase in personalized medicine, a rise in chronic illnesses, a higher number of hospitals and diagnostic laboratories, and a surge in demand for early disease detection. Notable trends for the forecast period comprise technological progression, an escalation in non-invasive testing preference, development of new products, strategic partnerships, and the emergence of innovative biomarkers for neurological disorders.

Get your neurogenetic testing market report here!

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

What key factors are fueling the growth of the neurogenetic testing market?

The escalating incidence of neurological disorders is anticipated to boost the growth of the neurogenetic testing market. These disorders pertain to any complications that impair the nervous system, comprising the brain, spinal cord, and nerves. Genetic predisposition, infections, trauma, toxins, autoimmune reactions, and degeneration are the main causes of these neurological disorders. Neurogenetic testing plays a significant role in diagnosing, treating, and managing neurological disorders by providing a customized understanding of genetic risk factors, guiding treatment options, and enabling the individuals and their families to make educated healthcare decisions thus enhancing patient care and results. For example, in April 2022, the European Brain Council, a non-profit organization based in Belgium, reported that over 600 neurological diseases and close to 300 psychiatric conditions are causing suffering to millions across the world, including 65 million individuals with epilepsy. In Europe, 10.5 million individuals are dealing with dementia, and the number is projected to increase to 18.7 million by 2050. Therefore, this escalating incidence of neurological disorders is anticipated to spur the growth of the neurogenetic testing market.

Neurogenetic Testing Market Driver: Surge in Cancer Incidence Boosts Growth in Neurogenetic Testing Market

 

How is the global neurogenetic testing market divided into key segments?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Who are the key firms paving the way for growth in the neurogenetic testing market?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

What emerging trends are influencing the growth of the neurogenetic testing market?

Leading firms in the neurogenetic testing market, like Nucleus Genomics, are producing cutting-edge products such as whole-genome sequencing (WGS), which significantly expands the precision and reach of genetic assessments, enabling more detailed and personalized evaluations for neurological conditions. WGS is an extensive genomic assessment technique that involves identifying the full DNA sequence of a person’s total genome. For instance, in March 2024, Nucleus Genomics, a firm based in the US that offers genetic assessments, introduced a product for DNA evaluation. This platform empowers individuals with a deeper comprehension of their genetic traits, aiding them in making informed judgments about their health and overall well-being. Nucleus Genomics, with its advanced technology and professional genetic counseling services, is poised to transform the genetic testing landscape. By delivering the ability to perform whole-genome sequencing directly to the public, it’s revolutionizing genomic medicine.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16131

What regions are contributing significantly to the growth of the neurogenetic testing market?

North America was the largest region in the neurogenetic testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Prenatal And Newborn Genetic Testing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/prenatal-and-newborn-genetic-testing-global-market-report

Molecular Cytogenetics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/molecular-cytogenetics-global-market-report

Genetically Modified Animal Products Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/genetically-modified-animal-products-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the neurogenetic testing market size evolved in recent years?

The scale of the neurogenetic testing market has experienced rapid expansion lately. Its growth is anticipated to increase from $0.61 billion in 2024 to $0.7 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 13.9%. The significant development during the historic period is a result of the rise in the occurrence of neurological ailments, expanded research in the life science sector, a growing number of Parkinson’s disease patients, elevated cancer cases, and heightened awareness among healthcare experts.

What are the predictions for the neurogenetic testing market size in the coming years?

The market size for neurogenetic testing is projected to experience a swift expansion in the coming years, reaching $1.16 billion in 2029 with a 13.5% compound annual growth rate (CAGR). This growth during the forecast period is likely due to a variety of factors including an increase in personalized medicine, a rise in chronic illnesses, a higher number of hospitals and diagnostic laboratories, and a surge in demand for early disease detection. Notable trends for the forecast period comprise technological progression, an escalation in non-invasive testing preference, development of new products, strategic partnerships, and the emergence of innovative biomarkers for neurological disorders.

Get your neurogenetic testing market report here!

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

What key factors are fueling the growth of the neurogenetic testing market?

The escalating incidence of neurological disorders is anticipated to boost the growth of the neurogenetic testing market. These disorders pertain to any complications that impair the nervous system, comprising the brain, spinal cord, and nerves. Genetic predisposition, infections, trauma, toxins, autoimmune reactions, and degeneration are the main causes of these neurological disorders. Neurogenetic testing plays a significant role in diagnosing, treating, and managing neurological disorders by providing a customized understanding of genetic risk factors, guiding treatment options, and enabling the individuals and their families to make educated healthcare decisions thus enhancing patient care and results. For example, in April 2022, the European Brain Council, a non-profit organization based in Belgium, reported that over 600 neurological diseases and close to 300 psychiatric conditions are causing suffering to millions across the world, including 65 million individuals with epilepsy. In Europe, 10.5 million individuals are dealing with dementia, and the number is projected to increase to 18.7 million by 2050. Therefore, this escalating incidence of neurological disorders is anticipated to spur the growth of the neurogenetic testing market.

Neurogenetic Testing Market Driver: Surge in Cancer Incidence Boosts Growth in Neurogenetic Testing Market

 

How is the global neurogenetic testing market divided into key segments?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Who are the key firms paving the way for growth in the neurogenetic testing market?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

What emerging trends are influencing the growth of the neurogenetic testing market?

Leading firms in the neurogenetic testing market, like Nucleus Genomics, are producing cutting-edge products such as whole-genome sequencing (WGS), which significantly expands the precision and reach of genetic assessments, enabling more detailed and personalized evaluations for neurological conditions. WGS is an extensive genomic assessment technique that involves identifying the full DNA sequence of a person’s total genome. For instance, in March 2024, Nucleus Genomics, a firm based in the US that offers genetic assessments, introduced a product for DNA evaluation. This platform empowers individuals with a deeper comprehension of their genetic traits, aiding them in making informed judgments about their health and overall well-being. Nucleus Genomics, with its advanced technology and professional genetic counseling services, is poised to transform the genetic testing landscape. By delivering the ability to perform whole-genome sequencing directly to the public, it’s revolutionizing genomic medicine.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16131

What regions are contributing significantly to the growth of the neurogenetic testing market?

North America was the largest region in the neurogenetic testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Prenatal And Newborn Genetic Testing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/prenatal-and-newborn-genetic-testing-global-market-report

Molecular Cytogenetics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/molecular-cytogenetics-global-market-report

Genetically Modified Animal Products Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/genetically-modified-animal-products-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Does the Projected Growth of the Neurogenetic Testing Market Compare Over the Forecast Period?

There has been substantial growth recently in the neurogenetic testing market. The current forecast indicates an expansion from $0.61 billion in 2024 to $0.7 billion in 2025, maintaining a compound annual growth rate (CAGR) of 13.9%. This considerable growth during the historic period can be linked to factors such as the escalating prevalence of neurological illnesses, amplified research in the sphere of life sciences, mounting cases of Parkinson’s disease, an upsurge in cancer incidents, and heightened awareness among healthcare practitioners.

Forecasted to expand rapidly in the coming years, the neurogenetic testing market is predicted to reach a staggering $1.16 billion in 2029, growing at a compound annual rate (CAGR) of 13.5%. The reasons for this growth span a range of factors, from the increased uses in personalized medicine to the growing prevalence of chronic diseases. The rising number of hospitals and diagnostic labs, as well as a growing interest in early disease detection, also contribute to this growth. Key trends for the forecast period include technological advancements, the increasing preference for non-invasive testing methods, the development of new products, strategic collaborations, and the arrival of innovative biomarkers for neurological conditions.

Which Factors Are Enhancing the Growth of the Neurogenetic Testing Market?

The increase in cases of neurological disorders is predicted to fuel the expansion of the neurogenetic testing market. Neurological disorders encompass conditions that impact the brain, spinal cord, and nerves of the nervous system. These disorders can arise due to genetic predisposition, trauma, infections, toxins, autoimmune reactions, and degeneration. Neurogenetic testing greatly improves the diagnosis, treatment, and management of these disorders by providing personalized understanding of genetic risk factors, assisting in treatment choices, and enabling individuals and their families to make educated healthcare decisions, subsequently enhancing patient care and outcomes. In April 2022, the Belgium-based non-profit organization, the European Brain Council confirmed that worldwide, over 600 neurological diseases and nearly 300 psychiatric conditions affect millions, including 65 million epilepsy sufferers. Within Europe, dementia affects 10.5 million people and is forecasted to reach 18.7 million by 2050. Thus, the escalating prevalence of neurological disorders will trigger a growth in the neurogenetic testing market. The upsurge in instances of cancer is anticipated to fuel the expansion of the neurogenetic testing market. Cancer is known as a disease that causes abnormal cells to divide uncontrollably, which leads to the destruction of body tissue. The increase in cancer cases are due to factors such as the obesity crisis, inherited genetic abnormalities, viruses like hepatitis B and C, Epstein-Barr virus (EBV), and human papillomavirus (HPV). Neurogenetic testing plays a crucial role in the management of cancer by aiding in the selection of the most effective treatment course, evaluating prognoses, singling out high-risk patients and supplying individualized care based on each patient’s unique genetic profile and family history. For example, the US-based professional organization, the American Society of Clinical Oncology reported in May 2024 that there were an estimated 20 million new cancer cases in 2022, with predictions of 35 million new cases worldwide by 2050 accounting for 9.7 million deaths from the disease. Therefore, the surge in cancer incidence is steering the growth of the neurogenetic testing market.

Get Your Free Sample of the Global Neurogenetic Testing Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Who Are the Key Players Steering the Development of the Neurogenetic Testing Market?

Major companies operating in the neurogenetic testing market are:

• Thermo Fisher Scientific Inc._x000D_

• Mayo Clinic_x000D_

• Roche Diagnostics Corporation_x000D_

• Laboratory Corporation_x000D_

• Quest Diagnostics Incorporated_x000D_

How Are Consumer Trends Shaping the Current and Future Landscape of the Neurogenetic Testing Market?

Leading corporations in the neurogenetic testing market are introducing cutting-edge products like whole-genome sequencing to improve the precision and breadth of genetic analysis, thereby allowing more thorough and individualized testing for neurological conditions. Whole-genome sequencing (WGS) is an exhaustive genetic analysis approach that deciphers the full DNA sequence of a person’s entire genome. For example, in March 2024, Nucleus Genomics, a firm based in the US that specialises in genetic analysis, unveiled a DNA analysis product. This platform equips individuals with an in-depth comprehension of their genetic tendencies, aiding them in making informed choices about their health and wellness. Through advanced technology and skilled genetic counseling services, Nucleus Genomics is poised to transform the genetic testing sector, making whole-genome sequencing readily accessible to individuals and revolutionising genomic medicine.

Get Instant Access to the Global Neurogenetic Testing Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

What Are the Strategic Segments Comprising the Neurogenetic Testing Market and Their Growth Contributions?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

Which Geographical Regions Are Shaping the Neurogenetic Testing Market Growth?

North America was the largest region in the neurogenetic testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Characteristics That Define the Neurogenetic Testing Market?

Neurogenetic testing is a type of genetic testing that focuses on identifying genetic variations associated with neurological disorders or conditions affecting the nervous system. It is used for diagnosing, predicting, and managing neurological disorders, as well as facilitating research and the development of personalized treatment approaches in the field of neurology and genetics.

Browse Through More Similar Reports By The Business Research Company:

Prenatal And Newborn Genetic Testing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/prenatal-and-newborn-genetic-testing-global-market-report

Molecular Cytogenetics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/molecular-cytogenetics-global-market-report

Genetically Modified Animal Products Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/genetically-modified-animal-products-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: